Period:
Draw Mode:
| Volume | 469,553 |
|
|||||
| News | - | ||||||
| Day High | 7.7975 | Low High |
|||||
| Day Low | 7.23 | ||||||
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| Omeros Corporation | OMER | NASDAQ | Common Stock |
| Price Change | Change Percent | Stock Price | Last Traded
|
|
|---|---|---|---|---|
| -0.15 | -2.02% | 7.26 | 15:58:34 |
| Open Price | Low Price | High Price | Close Price | Prev Close |
|---|---|---|---|---|
| 7.45 | 7.23 | 7.7975 | 7.41 |
| Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
|---|---|---|---|---|---|
| 5,935 | 469,553 | $ 7.46 | $ 3,502,180 | - | 1.735 - 7.7975 |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| 15:58:36 | 50 | $ 7.25 | USD |
Omeros Corporation Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| $ 456.14M | 62.83M | 62.80M | $ 375.00k | $ -337.01k | - | -1,353.47 |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | $ - | - | - | 4.10% |
Omeros News
Loading Messages....
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical OMER Price Data
| Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 5.79 | 7.7975 | 5.78 | 7.03 | 648,931 | 1.47 | 25.39% |
| 1 Month | 5.15 | 7.7975 | 4.84 | 6.13 | 606,230 | 2.11 | 40.97% |
| 3 Months | 3.28 | 7.7975 | 3.051 | 5.50 | 510,316 | 3.98 | 121.34% |
| 6 Months | 2.04 | 7.7975 | 1.735 | 4.46 | 765,717 | 5.22 | 255.88% |
| 1 Year | 2.52 | 7.7975 | 1.735 | 4.05 | 832,057 | 4.74 | 188.1% |
| 3 Years | 14.68 | 25.49 | 1.735 | 9.17 | 865,631 | -7.42 | -50.54% |
| 5 Years | 19.80 | 27.00 | 1.735 | 11.36 | 758,903 | -12.54 | -63.33% |
Omeros Description
| Omeros Corp is a United States-based biopharmaceutical company. Its goal is to research, develop, and commercialize small-molecule and protein therapeutics targeting inflammation, coagulopathies, and disorders of the central nervous system. The company owns Omidria (phenylephrine and ketorolac injection), approved by the U.S. Food and Drug Administration and launched in the U.S. for use during cataract surgery and intraocular lens replacement. Its product pipeline is focused on complement-associated thrombotic microangiopathies; complement-mediated glomerulonephropathies; Huntington's disease and cognitive impairment; and addictive and compulsive disorders. |